TaiGen and HEC Start China Phase III Trial of Dual-Drug HCV Treatment
publication date: Apr 25, 2019
TaiGen Biotech, a Taipei infectious disease company, has started a China Phase III trial of a combination treatment for chronic hepatitis C. In 2016, TaiGen formed a $102 million JV with YiChang HEC ChangJiang to develop the oral dual-drug, direct-acting antiviral HCV treatment. TaiGen contributed China rights to furaprevir for a 49% stake in the JV, while HEC transferred China rights for yimitasvir, plus an undisclosed amount of cash, for 51% ownership. The companies expect to complete the Phase III trial in 2020. More details....
Stock Symbols: (TWO: 4157) (HK: 1558)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.